Sector News

Sanofi, Hanmi seal diabetes licence deal for up to $4.2 bln

November 6, 2015
Life sciences

(Reuters) – Sanofi has signed a licence deal with Hanmi Pharmaceutical to develop experimental, long-acting diabetes treatments, the French drugmaker said on Thursday, in a move to revive its diabetes division.

South Korea-based Hanmi will receive an upfront payment of 400 million euros ($434 million) and is eligible for up to 3.5 billion euros in development, registration and sales milestones, as well as double-digit royalties on net sales.

In return Sanofi will get an exclusive worldwide licence to develop and commercialise Hanmi’s so-called GLP-1 diabetes treatments. Hanmi will retain an exclusive option to co-commercialise the products in Korea and China.

The deal marks a sizeable bet by Sanofi on a new technology at a time when its all-important diabetes business is struggling.

Nearly 400 million people worldwide have diabetes, with type 2 accounting for more than 90 percent of cases. Without proper treatment or lifestyle changes those numbers are expected to grow substantially.

But Sanofi, which will unveil a five-year strategic plan on Friday, surprised investors last week when it said revenues at the division would keep falling until 2018, due to growing competition, especially in the United States.

Although he did not refer specifically to diabetes, Chief Executive Olivier Brandicourt had told reporters on a results call that he was considering acquisitions and licensing deals.

The tie-up with Hanmi means Sanofi is investing heavily in the long-acting area where competitors like Denmark’s Novo Nordisk and U.S.-based Eli Lilly are also active.

Nordea analyst Michael Novod said the move was “very bad news” for Denmark’s Zealand Pharma, which has an existing deal with Sanofi for a short-acting GLP-1 drug.

Zealand’s shares fell 5 percent while Sanofi rose 1.8 percent, slightly outperforming a 1.4 percent advance in the Stoxx Europe 600 healthcare sector index.

The agreement also illustrates the growing power of South Korea as a force in pharmaceutical research.

According to a study by Research and Markets published in May, the country is seen as one of the leaders in research and development in the Asia Pacific region thanks to the strong involvement of both the public and private sectors. ($1 = 0.9225 euros)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend